Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Bazedoxifene for Prevention of Glucocorticoid-induced Bone Loss in RA Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female RA patients ≥ 45 years old with self-reported postmenopausal for ≥12 months or prior hysterectomy with bilateral oophorectomy. Female patients ≥ 55 years old who had prior hysterectomy without oophorectomy or with unilateral oophorectomy.~* Having been receiving low to moderate dose of glucocorticoids (prednisone ≤7.5 mg/day or equivalent) for ≥3 months prior to entry. (When taking glucocorticoids PRN, prednisone ≥1mg/day in average.)~* Patients expected to be on glucocorticoid treatment for 3 months after entry.~* Patients with an osteopenic mean lumbar spine (LS; L1-L4) or femoral neck bone mineral density (BMD; -1 \< T-score \< -2.5)~* Patients who provide a written consent of participating in this study.~Exclusion Criteria:~* Patients with condition that may interfere with the evaluation of spinal or hip osteoporosis by DXA such as two or more vertebral (L1-L4) fractures or other vertebral deformity~* Patients with hypercoagulability risk factors or a history of deep vein thrombosis and pulmonary embolism~* History of allergic reactions or intolerance to bazedoxifene or other SERM~* Patients receiving bisphosphonates, parathyroid hormone, SERMs, or anticonvulsants therapies within 6 months prior to entry~* Patients with known bone disorders such as osteomalacia, renal osteodystrophy and hyperparathyroidism~* Patients with undiagnosed uterine bleeding~* Patients with severe renal impairment or creatinine clearance \<30ml/min

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Bazedoxifene & Calcium/Vit D (Type: ACTIVE_COMPARATOR): * Enrollment: 57~* Drug: Bazedoxifene 20 mg/day (Viviant)~* Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day)
- Calcium/Vit D (Type: ACTIVE_COMPARATOR): * Enrollment: 57~* Drug: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).